Study finds no increased risks for severe or nonsevere urinary tract infections with SGLT-2 inhibitor use compared with other second-line antidiabetic drugs in type 2 diabetes patients.
The antibiotic Recarbrio is a combination of imipenem-cilastatin and relebactam.
Many healthcare-associated, community-onset urinary tract infections develop after being discharged.
Correlation highest for UTI; smaller-magnitude associations seen for UTI with intracerebral hemorrhage
Spero Therapeutics announced that the Food and Drug Administration (FDA) has granted Fast Track designation for SPR994 (tebipenem pivoxil hydrobromide) for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)
Polymyxin B recommended for routine use in invasive infections; colistin preferred for lower UTI
Findings from a small study suggest it could be an effective, safe, and attractive alternative to fluoroquinolones, bacterial resistance to which is becoming increasingly prevalent.
Research team used novel algorithms to ID early symptoms of health declines in dementia patients.
For this study, the authors identified randomized controlled trials (RCTs) that compared SGLT2 inhibitors with placebo, no treatment, or another antidiabetic agent and reported on UTI outcome.
Poor clinical outcomes linked to extended spectrum cephalosporin-resistant Enterobacteriaceae.
